July 22, 2020 12:30 - 1:30 PM ET

Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics 

Summary

Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access. 

Access Recording

Access Webinar Slides

With hundreds of vaccine and therapeutic candidates in the pipeline, planning ahead for patient access is vital. This uncharted territory provokes important questions about regulatory pathways, pricing, government procurement, coverage, access, distribution, and more.  Avalere experts explored these questions and tipping points, as well as the necessary market access strategies.

Key Topics

FDA regulatory considerations and downstream implications 
Coverage and access challenges 
Pricing, procurement, and distribution scenarios
Potential 2020 election impacts on the COVID-19 response

Panelists

Moderator

Elizabeth Carpenter , Head of Advisory Services

Elizabeth specializes in policy, particularly in the implementation of the Affordable Care Act (ACA), trends in commercial insurance, drug pricing policy, and the impact of politics on the policy landscape.

Speaker

Kelly L. George , Consultant II, Commercialization & Regulatory Strategy

Kelly George supports clients in navigating the regulatory strategy and FDA policy environment for products in the space of drugs, biologics, and medical devices.

Speaker

Richard Hughes IV , Managing Director

Richard Hughes IV leads Avalere’s vaccines team, which supports clients with vaccine policy, market access and evidence strategies.

Speaker

John C. Neal , Managing Director, Commercialization & Regulatory Strategy

John C. Neal partners with pharmaceutical and biotech clients to develop market access assessments and launch strategies designed to ensure successful commercialization of assets.